France· FR:64976070
TRIZIVIR 300 mg / 150 mg / 300 mg, comprimé pelliculé
A medicinal product containing zidovudine + lamivudine + sulfate d'abacavir, registered in France by VIIV HEALTHCARE (PAYS-BAS), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ZIDOVUDINE + LAMIVUDINE + SULFATE D'ABACAVIR
- Manufacturer
- VIIV HEALTHCARE (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400936109285plaquette(s) PVC polychlortrifluoroéthylène PVC-Aluminium papier avec fermeture de sécurité enfant de 60 comprimé(s)EUR 314.48
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Zidovudine + lamivudine + sulfate d'abacavir in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRIZIVIRViiV Healthcare BV, Amersfoort
- SpainTRIZIVIR 300 MG/150 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- IrelandTrizivir 300 mg/150 mg/300 mg film-coated tabletsViiV Healthcare BV
- NetherlandsAbacavir/Lamivudine/Zidovudine Mylan 300 mg/150 mg/300 mg filmomhulde tablettenMylan Pharmaceuticals Limited
- United KingdomTrizivir 300mg/150mg/300mg tabletsViiV Healthcare UK Ltd
- FinlandTRIZIVIRViiV Healthcare BV
- IcelandTrizivirViiV Healthcare BV
- United StatesABACAVIR, LAMIVUDINE AND ZIDOVUDINELupin Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Iceland · Trizivir
- Italy · Abacavir/Lamivudina/Zidovudina Mylan
- Liechtenstein · Trizivir
- Netherlands · Abacavir/Lamivudine/Zidovudine Mylan
- Norway · Trizivir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e583124e-4796-4ae2-bd9c-235c4aff0f50 GET /v1/drugs/e583124e-4796-4ae2-bd9c-235c4aff0f50?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64976070",
"date_amm": "2000-12-28",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/00/156",
"substance": "ZIDOVUDINE + LAMIVUDINE + SULFATE D'ABACAVIR",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about zidovudine + lamivudine + sulfate d'abacavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.